Abstract
1 Plasma concentrations of oxprenolol have been compared in six healthy volunteers after 80 and 160 mg doses of a new slow release (SR) oxprenolol preparation, after an 80 ng dose of conventional oxprenolol (CO), and after the second of two 80 mg doses of conventional oxprenolol given 12 h apart. Basal pulse rates and blood pressures, and pulse rates before and after a standard exercise test have been compared after the four active treatments and after a placebo. 2 Peak plasma concentrations of oxprenolol attained after 160 mg of the slow release preparation were similar to the peak concentrations after the single 80 mg dose of conventional oxprenolol. Higher concentrations, however, persisted for much longer after the slow release preparations than after the conventional preparations. 3 Neither oxprenolol formulation had any effect on resting pulse rate or blood pressure in normotensive volunteers. 4 Comparison with placebo showed that the single dose of the conventional oxprenolol produced a significant reduction in exercise induced tachycardia for 8 h whereas the high dose of the slow release preparation produced a similar reduction which lasted for at least 14 hours.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brunner L., Imhof P., Jack D. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man. Eur J Clin Pharmacol. 1975;8(1):3–9. doi: 10.1007/BF00616408. [DOI] [PubMed] [Google Scholar]
- Gatley M. S. To be taken as directed. J R Coll Gen Pract. 1968 Jul;16(1):39–44. [PMC free article] [PubMed] [Google Scholar]
- Johnsson G., Regårdh C. G., Sölvell L. Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):31–44. doi: 10.1111/j.1600-0773.1975.tb03320.x. [DOI] [PubMed] [Google Scholar]
- MASTER A. M. The two-step exercise electrocardiogram: a test for coronary insufficiency. Ann Intern Med. 1950 May;32(5):842–863. doi: 10.7326/0003-4819-32-5-842. [DOI] [PubMed] [Google Scholar]
- Perrier D., Gibaldi M., Boyes R. N. Prediction of systemic availability from plasma-level data after oral drug administration. J Pharm Pharmacol. 1973 Mar;25(3):256–257. doi: 10.1111/j.2042-7158.1973.tb10634.x. [DOI] [PubMed] [Google Scholar]
- Regårdh C. G., Borg K. O., Johansson R., Johnsson G., Palmer L. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974 Aug;2(4):347–364. doi: 10.1007/BF01061407. [DOI] [PubMed] [Google Scholar]
- Taylor S. H., Meeran M. K. Different effects of adrenergic beta-receptor blockade on heart rate response to mental stress, catecholamines, and exercise. Br Med J. 1973 Nov 3;4(5887):257–259. doi: 10.1136/bmj.4.5887.257. [DOI] [PMC free article] [PubMed] [Google Scholar]